Detalhe da pesquisa
1.
Determining treatment tolerance and fitness for intensive chemotherapy in older adults with AML: a call to action.
Blood
; 143(6): 483-487, 2024 Feb 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-38048592
2.
Follow-up from the A041202 study shows continued efficacy of ibrutinib regimens for older adults with CLL.
Blood
; 143(16): 1616-1627, 2024 Apr 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-38215395
3.
Genome Sequencing as an Alternative to Cytogenetic Analysis in Myeloid Cancers.
N Engl J Med
; 384(10): 924-935, 2021 03 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-33704937
4.
The role of allogeneic transplant for adult Ph+ ALL in CR1 with complete molecular remission: a retrospective analysis.
Blood
; 140(20): 2101-2112, 2022 11 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-35877996
5.
Systemic IL-15 promotes allogeneic cell rejection in patients treated with natural killer cell adoptive therapy.
Blood
; 139(8): 1177-1183, 2022 02 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-34797911
6.
Molecular responses in decitabine- and decitabine/venetoclax-treated patients with acute myeloid leukemia and myelodysplastic syndromes.
Haematologica
; 2024 Apr 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-38618679
7.
Immunosuppression and outcomes in adult patients with de novo acute myeloid leukemia with normal karyotypes.
Proc Natl Acad Sci U S A
; 118(49)2021 12 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-34845035
8.
Flotetuzumab as salvage immunotherapy for refractory acute myeloid leukemia.
Blood
; 137(6): 751-762, 2021 02 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-32929488
9.
Acute Myeloid Leukemia, Version 3.2023, NCCN Clinical Practice Guidelines in Oncology.
J Natl Compr Canc Netw
; 21(5): 503-513, 2023 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-37156478
10.
Ivosidenib induces deep durable remissions in patients with newly diagnosed IDH1-mutant acute myeloid leukemia.
Blood
; 135(7): 463-471, 2020 02 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-31841594
11.
Clinical and molecular relevance of genetic variants in the non-coding transcriptome of patients with cytogenetically normal acute myeloid leukemia.
Haematologica
; 107(5): 1034-1044, 2022 05 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34261293
12.
BL-8040 CXCR4 antagonist is safe and demonstrates antileukemic activity in combination with cytarabine for the treatment of relapsed/refractory acute myelogenous leukemia: An open-label safety and efficacy phase 2a study.
Cancer
; 127(8): 1246-1259, 2021 04 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-33270904
13.
Mutation Clearance after Transplantation for Myelodysplastic Syndrome.
N Engl J Med
; 379(11): 1028-1041, 2018 Sep 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-30207916
14.
Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML.
N Engl J Med
; 378(25): 2386-2398, 2018 Jun 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-29860938
15.
Acute Lymphoblastic Leukemia, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology.
J Natl Compr Canc Netw
; 19(9): 1079-1109, 2021 09 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-34551384
16.
Phase 1 study of the MDM2 antagonist RO6839921 in patients with acute myeloid leukemia.
Invest New Drugs
; 38(5): 1430-1441, 2020 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-32020437
17.
A phase 1 study of the MDM2 antagonist RO6839921, a pegylated prodrug of idasanutlin, in patients with advanced solid tumors.
Invest New Drugs
; 38(4): 1156-1165, 2020 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-31734832
18.
The effect of donor type on outcomes in adults with acute myeloid leukemia after reduced-intensity hematopoietic peripheral blood cell transplant - a retrospective study.
Transpl Int
; 33(9): 1089-1098, 2020 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-32468720
19.
TP53 and Decitabine in Acute Myeloid Leukemia and Myelodysplastic Syndromes.
N Engl J Med
; 375(21): 2023-2036, 2016 11 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-27959731
20.
Mobilization of allogeneic peripheral blood stem cell donors with intravenous plerixafor mobilizes a unique graft.
Blood
; 129(19): 2680-2692, 2017 05 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-28292947